These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 10979714)

  • 21. Response to letter by Wang et al.: Comparing cardioprotection by remote ischaemic preconditioning in patients with and without diabetics.
    Kottenberg E; Peters J
    Acta Anaesthesiol Scand; 2014 Jul; 58(6):769. PubMed ID: 24850086
    [No Abstract]   [Full Text] [Related]  

  • 22. The role of hypoglycemic sulphonylureas in arrhythmias contributing to the mortality in acute myocardial ischemia.
    Koltai MZ; Aranyi Z; Ballagi-Podány G; Pogátsa G
    Acta Physiol Hung; 1990; 75 Suppl():175-6. PubMed ID: 2371854
    [No Abstract]   [Full Text] [Related]  

  • 23. Summaries for patients. How do older diabetes drugs compare in their effects on heart and blood vessel disease?
    Ann Intern Med; 2012 Nov; 157(9):I-28. PubMed ID: 23128878
    [No Abstract]   [Full Text] [Related]  

  • 24. [Measures to meet the side effects of sulfonylurea (SU) in the treatment of type 2 diabetes].
    Furukawa H; Ishida H
    Nihon Rinsho; 2002 Sep; 60 Suppl 9():357-61. PubMed ID: 12387018
    [No Abstract]   [Full Text] [Related]  

  • 25. The UK Prospective Diabetes Study.
    Kerner W
    Lancet; 1998 Dec; 352(9144):1934. PubMed ID: 9863811
    [No Abstract]   [Full Text] [Related]  

  • 26. [Glimepiride-induced cute cholestatic hepatitis].
    Heurgué A; Bernard-Chabert B; Higuero T; Lukas-Croisier C; Caron J; Cadiot G; Thiéfin G
    Ann Endocrinol (Paris); 2004 Apr; 65(2):174-5. PubMed ID: 15247878
    [No Abstract]   [Full Text] [Related]  

  • 27. Don't throw the baby out with the bath water: mortality with combination metformin and sulfonylurea.
    Tayek JA
    Diabetes Metab Res Rev; 2007 Feb; 23(2):85-6. PubMed ID: 17262894
    [No Abstract]   [Full Text] [Related]  

  • 28. Cardiovascular safety of sulphonylurea: comment on the study by Monami et al.
    Du L; Chen Y; Shen J; Peng Y; Sun X
    Diabetes Obes Metab; 2014 Jul; 16(7):667-9. PubMed ID: 24320700
    [No Abstract]   [Full Text] [Related]  

  • 29. Glimepiride-induced vasculitis: a case report.
    Ben Salem C; Hmouda H; Bouraoui K
    Br J Clin Pharmacol; 2007 Jul; 64(1):113-4. PubMed ID: 17324240
    [No Abstract]   [Full Text] [Related]  

  • 30. Antidiabetic treatments and risk of hospitalisation with myocardial infarction: a nationwide case-control study.
    Horsdal HT; Søndergaard F; Johnsen SP; Rungby J
    Pharmacoepidemiol Drug Saf; 2011 Apr; 20(4):331-7. PubMed ID: 21442682
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The risk of overall mortality in patients with type 2 diabetes receiving glipizide, glyburide, or glimepiride monotherapy: a retrospective analysis.
    Pantalone KM; Kattan MW; Yu C; Wells BJ; Arrigain S; Jain A; Atreja A; Zimmerman RS
    Diabetes Care; 2010 Jun; 33(6):1224-9. PubMed ID: 20215447
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Possible risk of sulfonylureas in the treatment of non-insulin-dependent diabetes mellitus and coronary artery disease.
    Mühlhauser I; Sawicki PT; Berger M
    Diabetologia; 1997 Dec; 40(12):1492-3. PubMed ID: 9447960
    [No Abstract]   [Full Text] [Related]  

  • 33. Glimepiride for NIDDM.
    Med Lett Drugs Ther; 1996 May; 38(975):47-8. PubMed ID: 8632731
    [No Abstract]   [Full Text] [Related]  

  • 34. Sulphonylureas in the treatment of non-insulin-dependent diabetes.
    Ferner RE; Alberti KG
    Q J Med; 1989 Nov; 73(271):987-95. PubMed ID: 2695959
    [No Abstract]   [Full Text] [Related]  

  • 35. [Glimepiride-induced acute hepatitis].
    Dusoleil A; Condat B; Sobesky R; Pelletier G; Buffet C
    Gastroenterol Clin Biol; 1999 Oct; 23(10):1096-7. PubMed ID: 10592884
    [No Abstract]   [Full Text] [Related]  

  • 36. Cardiovascular effects of diabetes drugs: emerging from the dark ages.
    Nissen SE
    Ann Intern Med; 2012 Nov; 157(9):671-2. PubMed ID: 23128866
    [No Abstract]   [Full Text] [Related]  

  • 37. Late complications of diabetes mellitus: risk factors in patients on sulfonylureas for more than 10 years.
    Hoshi M; Fujita S
    Jpn J Med; 1991; 30(6):616-7. PubMed ID: 1798228
    [No Abstract]   [Full Text] [Related]  

  • 38. The Ser1369Ala variant of ABCC8 and the risk for severe sulfonylurea-induced hypoglycemia in German patients with Type 2 diabetes.
    Holstein JD; Kovacs P; Patzer O; Stumvoll M; Holstein A
    Pharmacogenomics; 2012 Jan; 13(1):5-7; author reply 9-10. PubMed ID: 22176616
    [No Abstract]   [Full Text] [Related]  

  • 39. [Acute glimepiride-induced pancreatitis].
    Duboeuf T; De Widerspach-Thor A; Scotto B; Bacq Y
    Gastroenterol Clin Biol; 2004 Apr; 28(4):409-10. PubMed ID: 15146162
    [No Abstract]   [Full Text] [Related]  

  • 40. Can people with type 2 diabetes live longer than those without? A comparison of mortality in people initiated with metformin or sulphonylurea monotherapy and matched, non-diabetic controls.
    Bannister CA; Holden SE; Jenkins-Jones S; Morgan CL; Halcox JP; Schernthaner G; Mukherjee J; Currie CJ
    Diabetes Obes Metab; 2014 Nov; 16(11):1165-73. PubMed ID: 25041462
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.